NGL Fine-Chem Ltd.

NGLFINE

₹1359.6

0.47% (6.4)

Market Cap

₹841 Cr.

P/E

40.29

Key Ratios

Edit Ratio's

Market cap

841 Cr

40.29

Prom Holding

72.74 %

ROE (%)

7.39

ROCE (%)

9.85

Div Yield (%)

0.13

Sales

381 Cr

OPM (%)

8.89 %

Debt to Equity

0.27

Edit Ratio's

About

NGL Fine-Chem Ltd is a manufacturer of pharmaceuticals and intermediates for usage in veterina… Read more

Low

957

52W Range

High

2199

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Other Income

Other income component is making ratios of the company look optically better
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Asset turnover is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Current vs Historic Valuation

Company is trading at a discount to 3yr historic valuations
Debt

Company should not have issues servicing its debt
Sales Growth

Sales of the company has grown at a good pace
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Capex vs ROCE

Roce of the company has decreased even without significant capex
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

Total reactor capacity (kL)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

FAQs on NGL Fine-Chem Ltd. Business

What does NGL Fine-Chem do?

NGL Fine-Chem Ltd specializes in manufacturing pharmaceuticals and intermediates for veterinary and human health, providing high-quality customizable solutions to global companies.

Who are the competitors of NGL Fine-Chem?

NGL Fine-Chem major competitors are Hikal, Sequent Scientific, Kopran, Shree Ganesh Remed., Themis Medicare, Everest Organics, Nectar Lifesciences.
Market Cap of NGL Fine-Chem is ₹837 Crs.
While the median market cap of its peers are ₹851 Crs.

Is NGL Fine-Chem financially stable compared to its competitors?

NGL Fine-Chem seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Companies Doing Major Expansion

Companies in any sector undergoing sizeable expansion

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation	May Aug	Feb Mar Jun Sep Dec	Mar Jun Sep Dec	Feb Mar May Jun Aug Sep Dec	Mar Jun Sep Dec
Conference Call	Mar	Mar Sep	Mar Sep	Mar Jun Sep	Jun Sep Dec	Mar Sep	Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

NGL Fine-Chem Ltd.

Market Leadership in Anmial API's - SOIC

Rahul Nachane, MD, NGL Fine-Chem - Interview - Indian Business Tv

View the discussion on ValuePickr

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

NGL Fine-Chem Ltd.

NGL Fine-Chem Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

8 Yes

2 Neutral

7 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Pledge

Promoter Holding

Depreciation Effect

Retail Holding

Other Income

Revenue Recognition

Price & Performance

ROE

Share price

Working Capital

Current vs Historic Valuation

Debt

Sales Growth

Balance Sheet Strength

Capex vs ROCE

Margin Stability

ROCE Strength

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Corporate Actions

FAQs on NGL Fine-Chem Ltd. Business

What does NGL Fine-Chem do?

Who are the competitors of NGL Fine-Chem?

Is NGL Fine-Chem financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE